Open for inclusion

A phase Ia/Ib, first-in-human, open label, multicentre, dose-escalation and dose-expansion study of a novel NanoZolidĀ®-docetaxel depot formulation (NZ-DTX Depot) given as an intra-tumoural injection in patients with advanced solid tumours

Cancer type: Solide tumores

Phase: I

Principal Investigator: Yachnin Jeffrey

Country: SE

Keywords: Sweden, Stockhom, Nano, NZ-DTX Depot, Nano-zolid

Status: Open for inclusion